Objectives. To investigate genotypephenotype correlation and geneenvironment interaction between PTPN22 R620W environmental factors such as tobacco/hormonal treatments in an inception cohort of RA patients.
Introduction
Genegene and geneenvironment interactions are key features in the development of RA and other complex diseases. To date, the main pathogenesis hypothesis would be an interaction between the HLA-DRB1-shared epitope alleles (HLA-DRB1*SE) and tobacco smoking as risk factor for the production of anti-citrullinated protein/peptide antibodies (ACPAs), and then the development of RA [12] .
Other genetic and environmental factors could play a role in the pathogenesis of RA. The protein tyrosine phosphatase non-receptor 22 (PTPN22) rs2476601 single nucleotide polymorphism (SNP) has been identified as a susceptibility genetic factor for various autoimmune diseases including RA [3] . This association would be restricted to the rheumatoid factor (RF) and/or the ACPA positive subset. [4, 5] .
Regarding others environmental risk factors, two meta-analyses of casecontrol and cohort studies suggested a protective effect of oral contraception (OC) regarding RA susceptibility [6, 7] . More recently, we have reported that hormonal replacement therapy (HRT) may reduce the risk of anti-CCP antibody production in RA women carrying HLADRB1*01 and/or HLADRB1*04 alleles [8] . Therefore, our objectives were (i) to perform a PTPN22 rs2476601 genotypephenotype correlation analysis; (ii) to test for interactions between PTPN22 and environmental factors (tobacco smoking and global hormonal exposure) as influencing both ACPA and erosive status in RA, using intra-cohort analyses.
Methods

Study population and design
The Evaluation et Suivi des POlyarthrites Indiffé rencié es Ré centes (ESPOIR) cohort has been previously described (French cohort of early arthritis) [8, 9] . The study was approved by the Institutional Review Board of the Montpellier University Hospital, which was the coordinating centre for this cohort. Before inclusion, all patients gave their written informed consent to participate in this prospective follow-up study.
From the 813 patients recruited from November 2002 to April 2005 with early polyarthritis, 532 were Caucasian with a diagnosis of RA by Year 1 and an available PTPN22 rs2476601 genotype. RA was defined by fulfilment of the ACR 1987 criteria either at baseline, 6-or 12-month follow-up visit.
All the subjects of the ESPOIR sample were genotyped for the PTPN22 rs2476601 SNP using a competitive allelespecific PCR system (Kaspar genotyping, Kbioscience, Hoddeston, UK) and Taqman SNP genotyping assay allelic discrimination method (Applied Biosystems, Foster City, CA, USA) as previously described [10] . The average genotype completeness was 98%. The accuracy was >99%, according to duplicate genotyping of 10% of all samples. HLADRB1 genotypes (*01 and/or*04) were determined in each centre.
As outcomes, we chose the presence of ACPA at baseline and the presence of at least one erosion at 1 year (on hand and foot X-rays). As potential risk factors, we assessed the presence of the PTPN22 620W risk allele (as none/any), cigarette smoking as never/ever and categorized as <10 or 510 pack-years and hormonal treatments (HRT and/or OC, never/ever). The main characteristics of the study population are summarized in Table 1 .
Statistical analyses
Means and standard deviation (SD) were used to summarize continuous data and categorical data are summarized by counts and percentages. Student's t-test was used to compare most continuous variables between groups formed by anti-CCP or the presence of erosions by Year 1. For highly skewed data, the MannWhitney U test was used. For categorical variables, comparisons were made using Pearson's chi-square or Fisher's exact test.
To investigate the relationship between the PTPN22 620W risk allele and the two environmental factors in RA patients, we used two methods:
(i) Association measures: the dependence of each outcome on potential predictors was assessed using logistic regression and adjusting for potential confounding factors which were selected using the data in the literature and the results of the univariate analysis (P < 0.20) [11, 12] . For the model-building process of logistic regressions, we avoided assessing in the same model highly correlated covariates. For the assessment of geneenvironment interactions on an additive scale, we estimated the relative excess risk due to interaction (RERI), attributable proportion (AP) and the synergy index (SI). RERI and AP of 0, and SI of 1 indicate no interaction. Multiplicative interaction was assessed by adding an interaction variable (product of the gene and environmental factor individual effects) to the logistic regression models [14] . Analyses were performed using Statistical Package for the Social Sciences software for windows version 16.0 (SPSS Inc., Chicago, IL, USA). A P-value of <0.05 was taken to indicate statistical significance. For estimations of RERI, AP and SI, we used the Microsoft Excel spreadsheet provided by G.Y. Zou [15] .
Results
Effects of PTPN22 620W risk allele, smoking and the combination of both on the presence of ACPA at baseline or erosions at 1 year
Effect on the ACPA status
Univariate analysis found the PTPN22 620W risk allele significantly associated with the presence of ACPA (OR = 2.21, 95% CI 1.4, 3.4, P < 0.0001). Conversely, no association with tobacco smoking was detected (OR = 1.19, 95% CI 0.8, 1.7, P = 0.30). RA ACPA-positive (ACPA + ) patients who carried the PTPN22 620W risk allele and who have ever smoked, had an OR of 3.09 (95% CI 1.7, 5.7); P < 0.0001. After adjustment for several confounding factors using logistic regression, we confirmed these results www.rheumatology.oxfordjournals.org (Table 2) . Smoking alone was not associated with ACPA + status, whatever the cumulative dose. However, in patients who carried the PTPN22 620W risk allele, smoking appeared as a risk factor for the presence of ACPA with a smoking dose effect as suggested by the increase in the ORs associated with cumulative dose of tobacco (<10 pack-years and 510 pack-years). These findings suggested an interaction of a combined effect of the PTPN22 620W risk allele and cigarette smoking (OR = 4.28, 95% CI 2.0, 9.2, P < 0.0001) was larger than the sum and the product of individual effects. Nevertheless, this was not confirmed using interaction measures: RERI and AP were not significantly different from 0 and SI from 1, even in heavy smokers (at least 10 pack-years).
Effect on the early erosive status
Regarding the progress of erosions at 1 year, univariate analysis found no association with the PTPN22 620W risk allele (OR = 1.12, 95% CI 0.7, 1.8, P = 0.63). Of most interest, tobacco smoking was found to be associated with RA erosive status, acting with a protective effect (OR = 0.56, 95% CI 0.4, 0.8, P = 0.003). Multivariate logistic regression after adjustment for several confounding factors confirmed that smoking reduces significantly the risk of bone erosion (OR = 0.25, 95% CI 0.1, 0.6, 
P = 0.002). No interaction between the PTPN22 620W risk allele and tobacco was detected (Table 2).
Effects of PTPN22 620W risk allele, hormonal treatments in women and the combination of both on the presence of ACPA at baseline or erosions at 1 year
Effect on the ACPA status
After adjustment for several confounding factors, multivariate logistic regression analysis confirmed the results of univariate analysis (data not shown): the PTPN22 620W risk allele was associated with ACPA + status (OR = 2.13, 95% CI 1.3, 3.5, P = 0.003). Interestingly, global exposure to hormonal therapy was found to decrease the risk of ACPA production (OR = 0.44, 95% CI 0.3, 0.7, P = 0.001), independently of HLADR status. When both factors were combined, no influence of the combined factors was observed (OR = 0.91, 95% CI 0.4, 1.8, P = 0.78), suggesting an antagonistic geneenvironment interaction. However, interaction measures did not confirm such interaction (Table 3) .
Effect on erosion status
Neither carrying PTPN22 620W risk allele, hormonal treatments nor the combination of both were associated with the presence of bone erosions at 1 year (Table 3) .
Discussion
The results of the study reported herein provide evidence for a contribution of the PTPN22 620W risk allele to ACPA production, but not to early bone erosion. Further casecontrol association studies have reported such association between PTPN22 and ACPA-positive RA [4, 5] . However, only three have focused on intra-cohort analysis, which can provide an estimate of the true contribution of a genetic susceptibility factor to a specific phenotype regarding a given disease [1618] . Regarding structural damage, two previous intra-cohort analyses have been published with opposite results: an association was found with PTPN22 in the European Research on Incapacitating DIsease and Social Supports (EURIDISS) cohort but not in the Leiden Early Arthritis Cohort (EAC) cohort [19, 20] . Hence, PTNP22 appears to be a RA for presence of anti-CCP: gender, BMI, age at baseline, HLADR1 and/or DR4, CVD, malignancy, diabetes, hypercholesterolaemia and hypertriglyceridaemia; and for the presence of erosions: gender, age at baseline, HLADR1 and/or DR4, anti-TNF ever, MTX ever, number of DMARDs received, oral steroids ever, presence of anti-CCP at baseline, HAQ score and DAS-28 score at baseline. b P-value for multiplicative interaction term between PTPN22 risk allele*smoking.
www.rheumatology.oxfordjournals.org susceptibility factor and also a genetic factor influencing the RA phenotype (i.e. ACPA production), but not structural damage.
Unlike the reported casecontrol studies comparing RA cases with controls [20] or with undifferentiated arthritis [21] , no interaction between smoking and PTPN22 on ACPA production was observed in our RA intra-cohort analysis. Nevertheless, this result was in accordance with Kallberg et al.'s [22] study performed in two RA cohorts. Other RA intra-cohort analyses are required to better understand the role of both PTPN22 and smoking in ACPA production.
In good agreement with two large intra-cohort studies, cigarette smoking was detected as a protective environmental factor against bone erosion with a dose effect [23, 24] . Conversely, a worse radiographic outcome in RA patients who have ever smoked was detected in a very small sample size, possibly explaining such discrepancy [25] .
We have previously reported protective effect on the production of anti-CCP of HRT in patients who carry HLA-DRB1*01 and/or HLA-DRB1*04 [8] . Interestingly, the present study provides evidence for a direct role of hormonal exposure by protecting against ACPA production, independently of both PTPN22 and HLA-DRB1.
Methodological limitations of genetic and environmental studies must always be considered. Indeed, many studies that could not be replicated in independent groups appear statistically underpowered in the field of complex genetic diseases and are often shown to be falsely positive. Appropriate sample sizes are critical for detecting slight differences between two populations, as expected in these diseases, and efforts to recruit large cohorts are mandatory to provide sufficient statistical power. For association measures, the number of patients included seems to be sufficient. Nevertheless, the lack of interaction between the PTPN22 R620W variant and environmental factors could be due to the lack of power for interaction measures: calculations showed a power of $55% for interaction measures [26] . Moreover, the genetic background of the studied population should be as homogeneous as possible, thereby limiting the possibility of result bias by population stratification. To avoid these biases, we have focused on European Caucasian individuals and recruited a large sample size through the French networks to detect any association that thus highly favoured the validity of the observed association. Nonetheless, independent RA intra-cohort analysis is mandatory to provide a reliable replication of our results, which could be interpreted as conflicting with those previously reported in casecontrol studies.
In conclusion, the current report confirmed the involvement of PTPN22 in ACPA production and provides evidence for a direct role of both hormonal exposure and tobacco smoking as environmental factors acting with a protective effect against ACPA production and early bone erosion, respectively. Interestingly, such associations were found to be independent of both PTPN22 and Adjusted ORs: for the presence of anti-CCP: smoking ever, BMI, age at baseline, HLADR1 and/or DR4, CVD, malignancy, diabetes, hypercholesterolaemia, hypertriglyceridaemia; and for the presence of erosions: smoking ever, age at baseline, HLADR1 and/or DR4, anti-TNF ever, MTX ever, number of DMARDs received, oral steroids ever, presence of anti-CCP at baseline, HAQ score and DAS-28 score at baseline.
b P-value for multiplicative interaction term between PTPN22 genotype and hormonal treatments.
HLA-DRB1 RA patient status. No evidence for a geneenvironment interaction was detected, suggesting that the three genetic and environmental factors investigated contribute independently to modulation of the RA phenotype. These data provide new insights into RA pathogenesis, underlying the pivotal role of environmental factors in the typical heterogeneity of RA.
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. Genephenotype correlation between PTPN22 risk allele and ACPA-positive RA. . In women, hormonal treatment appeared to be a protective factor against ACPA in RA. . No evidence for a geneenvironment interaction (between PTPN22 risk allele, hormonal treatment and smoking) was detected.
